

# Adverse Event Reporting



**Gabi Herbert**  
Clinical Research Data Coordinator III  
Cancer Research And Biostatistics (CRAB)  
SWOG Statistics and Data Management Center

SWOG Group Meeting  
Spring 2026









1





# Adverse Event (AE) Reporting: Outline

- Key Terms
- AE Information in SWOG Protocols
- Components of Reporting Adverse Events
  - CTCAE Terms and Grades
  - Attribution
  - Status code
- Online Data Submission: Adverse Events

2

# Key Terms




3

# Definition of Adverse Event

An **adverse event** is any unfavorable and unintended change in a patient's condition from the day protocol treatment began, regardless of cause.

An Adverse Event may be...

- A **new event** which was not pre-existing prior to initiation of study treatment
- A **pre-existing event which recurs** with increased severity (grade) or increased frequency following study drug administration
- An event present at the time of study drug administration which is **exacerbated** following initial study drug administration









4

# Adverse Event versus Toxicity

A **toxicity** is an adverse event considered related or possibly related to the study drug or intervention.

Both terms may be used in SWOG protocols depending on the context; however, **patient assessments and reporting should encompass the broader category of adverse events.**









5

# Examples of Adverse Events

- Nausea or vomiting caused by study treatment
- Worsening of allergic rhinitis from seasonal allergies
- Wrist fracture due to fall
- Abnormal lab result that was not present at baseline
- Increasing tumor pain
- COVID-19 infection and related symptoms




Unless otherwise specified, **all grades of adverse events** (1-5), including abnormal laboratory findings, **must be reported** on the study's Adverse Events Form (AE Form) regardless of clinical significance or attribution to protocol treatment.

6

## Serious Adverse Events (SAEs)

A **Serious Adverse Event (SAE)** is an unexpected or severe reaction to protocol treatment.

7




## Types of Adverse Event Reporting

**Routine reporting:** reporting of ALL adverse events, regardless of attribution or grade, unless otherwise specified

- Captured via Adverse Events eCRF at protocol-specified timepoints





**Expedited reporting:** reporting of adverse events meeting certain criteria (e.g. Serious Adverse Events and Adverse Events of Special Interest)

- Captured via Adverse Events eCRF and CTEP-AERS

8

## AE Information in SWOG Protocols









9

## Relevant Protocol Sections

Section #	Section Name
3	Drug Information
8	Toxicities to be Monitored and Dose Modifications
9	Study Calendar
14	Data Submission Schedule




...and don't forget the Master Forms Set in CTSU!

10

## Protocol Section 8.0 – Toxicities to be Monitored and Dose Modifications

- Lists **Toxicities** that may be seen on treatment and drugs to aid in **symptom management**
- Provides **Adverse Event Reporting Requirements**
- Indicates the Common Terminology Criteria for Adverse Events (CTCAE) version used for study reporting
- Lists **Dosage changes** required during treatment in response to AEs
- Provides names and **contact information** of physicians to reach for assistance

11

## Protocol Section 8.0 – Toxicities to be Monitored and Dose Modifications

**Dose Modifications – Talazoparib (BMN 673)**




Dose modifications should be made based on the observed toxicity, as summarized in the tables below.

DRUG	DOSE LEVEL	DOSE
Talazoparib BMN 673	Full	1000 mcg/day
	-1 Level	750 mcg/day
	-2 Level	500 mcg/day
	-3 Level	250 mcg/day
	-4 Level	Discontinue

**Table 1: Renal Impairment Dose Modifications**

Toxicity	Dose Modification
Grade 3	No hold on treatment required, treatment may continue at next lower dose
Grade 4	Hold protocol treatment until resolution to < Grade 2, treatment may then resume at the next lower dose

- Questions about dose mods should always be directed to the **Study Chairs**

12

## Protocol Section 9.0 – Study Calendar

9.0 STUDY CALENDAR

PHYSICAL	Safety Randomization Step 2	Treatment 4				DIT 7a Pre-Progression Follow-up	DIT 7c Post-Progression Follow-up
		Cycle 1	Cycle 2	Cycle 3	Cycle 4		
History & Physical Exam	X	X	X	X	X	X	X
Weight & Zubrod Performance Status	X	X	X	X	X	X	X
Disease Assessment	X			X		X	X
Baseline Adverse Event Assessment	X			X		X	X
Toxicity Assessment	X	X	X	X	X	X	X

C Toxicity assessment must continue until 30 days after the last dose of protocol treatment or until resolution of all acute adverse events, whichever is later.

- Assessments required where X is present
- Refer to study calendar footnotes for additional details
- Report all AEs through the end-of-cycle assessment
- “Late Adverse Events” may be captured during follow-up

13

## Master Forms Set (All CRFs)

- Available via CTSU (Document Type = Case Report Forms)
- Contains all case report forms (CRFs) for a particular protocol, including those used to report adverse events

14

## Master Forms Set (All CRFs)

15

## Reporting Adverse Events

CTCAE Terms and Grades  
Attribution  
Status Codes

16

## NCI Common Terminology Criteria for Adverse Events (CTCAE)

- CTCAE versions and other AE reporting resources are found at [ctep.cancer.gov](http://ctep.cancer.gov)
  - Current SWOG trials use Version 5.0, which was published in NOV 2017
  - Coming soon!** Version 6.0 was published in JUL 2025
    - Expected to be implemented in new SWOG trials starting later this year
- Some studies may use a different CTCAE version for routine AE reporting vs. SAE reporting.

**\*\*Reminder: Protocol section 8 lists the CTCAE version used in the trial\*\***

17



CTCAE Term	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
<b>Adverse event</b>	Systemic intervention not indicated	Oral intervention indicated	Bronchospasm, hospitalization indicated for clinical sequelae, intravenous intervention indicated	Life-threatening consequences, urgent intervention indicated	Death
<b>Anaphylaxis</b>		Symptomatic, bronchospasm, with or without urticaria, parenteral intervention indicated, allergy-related edema/angioedema, hypotension		Life-threatening consequences, urgent intervention indicated	Death
<b>Autoimmune disorder</b>	Asymptomatic; serologic or other evidence of autoimmune reaction, with normal organ function; intervention not indicated	Evidence of autoimmune reaction involving a non-essential organ or function (e.g., hypothyroidism)	Autoimmune reactions involving major organ (e.g., colitis, uveitis, myocarditis, kidney)	Life-threatening consequences, urgent intervention indicated	Death
<b>Cytokine release syndrome</b>	Fever with or without constitutional symptoms	Hypotension responding to fluids, hypoxia responding to 40% O2	Hypotension managed with one pressor, hypoxia requiring a 40% O2	Life-threatening consequences, urgent intervention indicated	Death
<b>Severe infection</b>	Asymptomatic; clinical or diagnostic observations only; intervention not indicated	Moderate arthralgia, fever, rash, urticaria, antibiotics indicated	Severe arthralgia or arthritis; extensive rash; steroids or IV fluids indicated	Life-threatening consequences, prior or ventilatory support indicated	Death

18

## Selecting CTCAE Terms



- CTCAE terms might not always be listed the way that you expect. Below are some examples of common AEs and their appropriate CTCAE v5.0 term:
  - Pneumonia → Lung infection
  - Thrombocytopenia → Platelet count decreased
  - Shortness of breath → Dyspnea
- Each system category includes an “Other, specify” option in the rare case there is no term is available for an adverse event. Please use “other” sparingly!

**CTRL+F is your BFF!**

19

CTCAE Term	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
<b>Anemia</b> Definition: A disorder characterized by a reduction in the amount of hemoglobin in 100 ml of blood. Signs and symptoms of anemia may include paleness of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability. Navigational Note: -	Hemoglobin (Hgb) <11L - 13.0 g/dL; <11N - 6.2 mmol/L; <11N - 100 g/L	High <10.8 - 8.0 g/dL; <6.2 - 4.9 mmol/L; <100 - 80g/L	High <8.0 g/dL; <4.9 mmol/L; <80 g/L; transfusion indicated	Life-threatening consequences; urgent intervention indicated	Death
<b>Bone marrow hypocellular</b> Definition: A disorder characterized by the inability of the bone marrow to produce hematopoietic elements. Navigational Note: -	Mildly hypocellular or <25% reduction from normal cellularity for age	Moderately hypocellular or <25 - <50% reduction from normal cellularity for age	Severely hypocellular or <50 - <75% reduction cellularity from normal for age	Aplastic persistent for longer than 2 weeks	Death
<b>Disseminated intravascular coagulation</b> Definition: A disorder characterized by systemic pathological activation of blood clotting mechanisms which results in clot formation throughout the body. There is an increase in the risk of hemorrhage as the body is depleted of platelets and coagulation factors. Navigational Note: -	-	Laboratory findings with no bleeding	Laboratory findings and bleeding	Life-threatening consequences; urgent intervention indicated	Death
<b>Eosinophilia</b> Definition: A disorder characterized by laboratory test results that indicate an increased number of eosinophils in the blood. Navigational Note: -	Adult and adolescent <500/mm <sup>3</sup>	>500 - <1500/mm <sup>3</sup>	>1500 - <5000/mm <sup>3</sup>	>5000/mm <sup>3</sup>	Death
<b>Fever of unknown origin</b> Definition: A disorder characterized by an ANC <1000/mm <sup>3</sup> and a single temperature of >38.3 degrees C (101.1 degrees F) or a sustained temperature of >=38 degrees C (100.4 degrees F) for more than one hour. Navigational Note: -	-	-	ANC <1000/mm <sup>3</sup> with a single temperature of >38.3 degrees C (101.1 degrees F) or a sustained temperature of >=38 degrees C (100.4 degrees F) for more than one hour	Life-threatening consequences; urgent intervention indicated	Death
<b>Hemolysis</b> Definition: A disorder characterized by laboratory test results that indicate widespread erythrocyte cell membrane destruction. Navigational Note: -	Laboratory evidence of hemolysis only (e.g., direct antiglobulin test; DAT; Coombs; schistocytes; decreased haptoglobin)	Evidence of hemolysis and >=2 g decrease in hemoglobin	Transfusion or medical intervention indicated (e.g., steroids)	Life-threatening consequences; urgent intervention indicated	Death






20

## Reporting Adverse Events: Attribution

The attribution code describes, in the opinion of the investigator, how likely it is that the adverse event is due to protocol treatment:

Relationship	Attribution	Description
Unrelated to Investigational Agent/Intervention	1- Unrelated	The AE is <i>clearly not</i> related to the intervention
	2- Unlikely	The AE is <i>doubtfully</i> related to the intervention
Related to Investigational Agent/Intervention	3- Possible	The AE <i>may be</i> related to the intervention
	4- Probable	The AE is <i>likely</i> to be related to the intervention
	5- Definite	The AE is <i>clearly</i> related to the intervention



21

## Reporting Adverse Events: Status Code

Some SWOG studies will collect **status** in addition to grade and attribution. The status code describes the state of the adverse event at various points throughout the study.

**Status Codes range from 1 to 3:**




- 1 = New
- 2 = Continues at same or lower grade
- 3 = Increased grade OR improved then worsened

22

## Online Data Submission

Adverse Events







23

## Online Data Submission: Adverse Events

SWOG has two EDC systems in use:

- CRA Workbench (legacy trials only)
- Medidata Rave

24

### Online Data Submission: Adverse Events

25

### Online Data Submission: Adverse Events

26

### Online Data Submission: Adverse Events

27

### Online Data Submission: Adverse Events

28

### Online Data Submission: Adverse Events

29

### Online Data Submission: Adverse Events

30

### Online Data Submission: Adverse Events

Use the arrow to select the attribution from the drop-down menu

31

### Online Data Submission: Adverse Events

Select all that apply

32

### Online Data Submission: Adverse Events

Add a new Log Line to the table

33

### Online Data Submission: Adverse Events

If you choose "Other," specify further in the text box

Use the Comments as needed for further explanation

34

### Online Data Submission: Adverse Events

Manually entering a term results in a nonconform data error

35

### Online Data Submission: Adverse Events

Add a new Log Line to the table

Adverse event term (CTCAE v5.0)	Attribution to study intervention	Hospitalization	Life-threatening	Death	Disability/Inconvenience	Congenital anomaly/birth defect	SAE report	AE report	Time zone
1 Cough	Unlikely	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	-	11 Apr 2023 06:52:44	Eastern Standard Time
2 Infections and infestations	Unlikely	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	-	11 Apr 2023 06:52:44	Eastern Standard Time
3 pneumonia	Unlikely	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	-	11 Apr 2023 06:52:44	Eastern Standard Time

36

### Online Data Submission: Adverse Events

Form Instructions: Red asterisks before a field denotes that it is required by the system for rules evaluation.

Start date of this case/report: 9 Dec 2020

Adverse event grade (CTCAE v5.0): [Dropdown menu]

SAE report recommended:

AE entry date (required): 11 Apr 2020 04:45:14 PM

Time zone (required): Eastern Standard Time

INSTRUCTIONS: After entering new or modified data in the table above, adverse events must be submitted to CTEP/AERS for rules evaluation by saving the Expedited Reporting Evaluation (RPE) in Home.

37

### Online Data Submission: Adverse Events

Form Instructions: Red asterisks before a field denotes that it is required by the system for rules evaluation.

Start date of this case/report: 9 Dec 2020

Adverse event grade (CTCAE v5.0): [Dropdown menu]

SAE report recommended:

AE entry date (required): 11 Apr 2020 04:45:14 PM

Time zone (required): Eastern Standard Time

INSTRUCTIONS: After entering new or modified data in the table above, adverse events must be submitted to CTEP/AERS for rules evaluation by saving the Expedited Reporting Evaluation (RPE) in Home.

38

### Online Data Submission: Adverse Events

Form Instructions: Red asterisks before a field denotes that it is required by the system for rules evaluation.

Start date of this case/report: 9 Dec 2020

Adverse event grade (CTCAE v5.0): [Dropdown menu]

SAE report recommended:

AE entry date (required): 11 Apr 2020 04:45:14 PM

Time zone (required): Eastern Standard Time

INSTRUCTIONS: After entering new or modified data in the table above, adverse events must be submitted to CTEP/AERS for rules evaluation by saving the Expedited Reporting Evaluation (RPE) in Home.

39

### Online Data Submission: Adverse Events

Adverse event description (CTCAE v5.0)	Attribution to study intervention	Hospitalization	Life-threatening	Death/Disability	Congestive heart failure	Other	SAE report recommended	AE entry date (required)	Time zone (required)
Cough	Unlikely	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	11 Apr 2020 06:00:00	Eastern Standard Time
Live infection	Unlikely	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	11 Apr 2020 06:00:00	Eastern Standard Time

Form Instructions: Red asterisks before a field denotes that it is required by the system for rules evaluation.

Start date of this case/report: 9 Dec 2020

INSTRUCTIONS: After entering new or modified data in the table above, adverse events must be submitted to CTEP/AERS for rules evaluation by saving the Expedited Reporting Evaluation (RPE) in Home.

40

### Online Data Submission: Adverse Events

Form Instructions: Red asterisks before a field denotes that it is required by the system for rules evaluation.

Start date of this case/report: 9 Dec 2020

Adverse event grade (CTCAE v5.0): [Dropdown menu]

SAE report recommended:

AE entry date (required): 11 Apr 2020 04:45:14 PM

Time zone (required): Eastern Standard Time

INSTRUCTIONS: After entering new or modified data in the table above, adverse events must be submitted to CTEP/AERS for rules evaluation by saving the Expedited Reporting Evaluation (RPE) in Home.

41

### Adverse Event Escape Room Assessment


Designed to cover the various aspects of adverse event in a fun, interactive learning environment.

- You are locked in a room and need to solve various clues related to adverse events.
- Each clue leads to a number in the code to escape the room.
- Resources are available on the bookshelf in the room.
- Use the QR code to access
- Click on the question mark to start.

Please send feedback to [ermete@swog.org](mailto:ermete@swog.org)

42




**Still have questions?**  
**Please email us:**



<p>BreastQuestion@crab.org  CancerControlQuestion@crab.org  GIQuestion@crab.org  GUQuestion@crab.org  GYNQuestion@crab.org  LeukemiaQuestion@crab.org</p>	<p>LungQuestion@crab.org  LungMAPQuestion@crab.org  LymphomaQuestion@crab.org  MelanomaQuestion@crab.org  MyelomaQuestion@crab.org  RareTumors@crab.org</p>
---	---

➤ Also refer to the *CRA Manual (for Oncology Research Professionals)*, available on the CRA Workbench!

---

43